{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:34:27Z","timestamp":1790534067938,"version":"4.1.0"},"reference-count":10,"publisher":"SAGE Publications","issue":"11-12","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1089\/hum.2022.29211.bfs","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T14:34:56Z","timestamp":1655130896000},"page":"573-576","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":23,"title":["Food and Drug Administration Lifts Clinical Hold on Pfizer Duchenne Muscular Dystrophy Gene Therapy Linked to Patient Death"],"prefix":"10.1177","volume":"33","author":[{"given":"Alex","family":"Philippidis","sequence":"first","affiliation":[{"name":"Mary Ann Liebert, Inc., Publishers, New Rochelle, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"e_1_3_1_2_2","unstructured":"Pfizer DMD Gene Therapy Team. Letter to the Duchenne Muscular Dystrophy community sent through Parent Project Muscular Dystrophy (PPMD). September 28 2021.. http:\/\/join.parentprojectmd.org\/site\/DocServer\/A_Message_from_Pfizer_on_our_DMD_Clinical_Program_-_Sept.pdf (last accessed May13 2022)."},{"key":"e_1_3_1_3_2","unstructured":"Pfizer. Pfizer to open first U.S. sites in Phase 3 trial of investigational gene therapy for ambulatory patients with duchenne muscular dystrophy. April 28 2022. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-open-first-us-sites-phase-3-trial-investigational (last accessed May13 2022)."},{"key":"e_1_3_1_4_2","unstructured":"Tessera Therapeutics. Tessera Therapeutics announces over $300M Series C financing to advance its GENE WRITING Platform. April 19 2022. https:\/\/www.businesswire.com\/news\/home\/20220419005210\/en\/Tessera-Therapeutics-Announces-Over-300M-Series-C-Financing-to-Advance-its-GENE-WRITING-Platform (last accessed May13 2022)."},{"key":"e_1_3_1_5_2","unstructured":"Astellas Pharma. Notice regarding impairment loss for products under development. April 22 2022. https:\/\/www.astellas.com\/en\/news\/25731 (last accessed May13 2022)."},{"key":"e_1_3_1_6_2","unstructured":"Caribou Biosciences. Caribou Biosciences announces positive initial data for CB-010 anti-CD19 allogeneic CAR-T cell therapy. May 12 2022. https:\/\/investor.cariboubio.com\/news-releases\/news-release-details\/caribou-biosciences-announces-positive-initial-data-cb-010-anti (last accessed May13 2022)"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","unstructured":"Nastoupil LJ O'Brien S Holmes HE et al. Firstin-human trial of CB-010 a CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knock out in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (ANTLER Study). European Hematology Association (EHA) 2022 Library May 12 2022.. https:\/\/library.ehaweb.org\/eha\/2022\/eha2022-congress\/358312\/loretta.j.nastoupil.first-in-human.trial.of.cb-010.a.crispr-edited.allogeneic.html (last accessed May13 2022).","DOI":"10.1097\/01.HS9.0000848676.15840.df"},{"key":"e_1_3_1_8_2","unstructured":"REGENXBIO. REGENXBIO reports first quarter 2022 financial results and recent operational highlights. May 4 2022. http:\/\/ir.regenxbio.com\/news-releases\/news-release-details\/regenxbio-reports-first-quarter-2022-financial-results-and (last accessed May13 2022)."},{"key":"e_1_3_1_9_2","doi-asserted-by":"crossref","unstructured":"Philippidis A. Scribe pursues CRISPR therapies with expanded Biogen Collaboration. Genetic Engineering & Biotechnology News May 12 2022. https:\/\/www.genengnews.com\/topics\/genome-editing\/scribe-pursues-crispr-therapies-with-expanded-biogen-collaboration\/ (last accessed May13 2022).","DOI":"10.1089\/gen.42.07.03"},{"key":"e_1_3_1_10_2","unstructured":"Scribe Therapeutics. Scribe Therapeutics expands collaboration with Biogen to second target. May 2 2022. https:\/\/www.scribetx.com\/press-release-scribe-therapeutics-expands-collaboration-with-biogen-to-second-target\/ (last accessed May13 2022)."},{"key":"e_1_3_1_11_2","unstructured":"Apertura Gene Therapy. Apertura Gene Therapy launches with $67M Series A financing from Deerfield and an Innovative Technology Platform to develop genetic medicines. April 22 2022.. https:\/\/aperturagtx.com\/2022\/04\/22\/apertura-gene-therapy-launches-with-67m-series-a-financing-from-deerfield-and-an-innovative-technology-platform-to-develop-genetic-medicines\/ (last accessed May13 2022)."}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2022.29211.bfs","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2022.29211.bfs","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2022.29211.bfs","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:56:10Z","timestamp":1777449370000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2022.29211.bfs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":10,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1089\/hum.2022.29211.bfs"],"URL":"https:\/\/doi.org\/10.1089\/hum.2022.29211.bfs","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}